Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Mol Cell Cardiol. 2024 Dec;197:1-4. doi: 10.1016/j.yjmcc.2024.10.001. Epub 2024 Oct 4.
Increasing interest in identifying the causes of and treatments for heart failure with preserved ejection fraction and cardiac fibrosis has spawned a focus on measures of cardiac diastolic function. The methods, their underlying principals and mechanics, and caveats to their measurement were largely worked out decades ago, but some of this seems a bit forgotten as scientists working in the field now have backgrounds more in molecular and cellular biology. This perspective was spawned by seeing the growing number of studies where diastolic function analysis is a key parameter used to justify a given pre-clinical model or to show the consequences of a particular genetic or pharmacological therapy. The goals are to discuss what comprises and influences diastolic function, how it is measured, what the parameters mean and what their limitations are, and what comprises evidence for pathophysiologically meaningful diastolic dysfunction.
人们对寻找射血分数保留型心力衰竭和心肌纤维化的病因和治疗方法越来越感兴趣,这使得人们关注心脏舒张功能的测量指标。这些方法、其基本原理和机制,以及测量时的注意事项在几十年前就已经基本确定,但由于现在从事该领域研究的科学家大多具有分子和细胞生物学背景,其中一些内容似乎有些被遗忘了。撰写本文的灵感来自于观察到越来越多的研究将舒张功能分析作为关键参数,用于证明特定的临床前模型或显示特定的遗传或药物治疗的后果。本文的目的是讨论舒张功能的组成和影响因素、如何进行测量、参数的含义及其局限性,以及构成病理生理学意义上舒张功能障碍的证据有哪些。